Stephane Vandenabeele
@cd80consulting.bsky.social
PhD Medical Biology / PharmD / Sloan London Business School
Co-Stimulation for Biotech Pharma
Views are my own, likes are not an endorsement, nor any investment or treatment guidance
Co-Stimulation for Biotech Pharma
Views are my own, likes are not an endorsement, nor any investment or treatment guidance
Reposted by Stephane Vandenabeele
another defeat in the war on stupid…
RFK Jr cancels $500m in funding for mRNA vaccines that counter viruses like Covid
RFK Jr cancels $500m in funding for mRNA vaccines that counter viruses like Covid www.bbc.com/news/article...
RFK Jr cancels $500m in funding for mRNA vaccines that counter viruses like Covid
RFK Jr cancels $500m in funding for mRNA vaccines that counter viruses like Covid www.bbc.com/news/article...
RFK Jr cancels $500m in mRNA vaccine development in the US
Since taking office, the vaccine sceptic has made a number of changes to how vaccines are regulated.
www.bbc.com
August 6, 2025 at 8:12 AM
another defeat in the war on stupid…
RFK Jr cancels $500m in funding for mRNA vaccines that counter viruses like Covid
RFK Jr cancels $500m in funding for mRNA vaccines that counter viruses like Covid www.bbc.com/news/article...
RFK Jr cancels $500m in funding for mRNA vaccines that counter viruses like Covid
RFK Jr cancels $500m in funding for mRNA vaccines that counter viruses like Covid www.bbc.com/news/article...
Reposted by Stephane Vandenabeele
Conan: You know, Anora is having a good night. That's great news. Two wins already. I guess Americans are excited to see somebody finally stand up to a powerful Russian.
March 3, 2025 at 3:08 AM
Conan: You know, Anora is having a good night. That's great news. Two wins already. I guess Americans are excited to see somebody finally stand up to a powerful Russian.
Reposted by Stephane Vandenabeele
I’ve got to admit it, Grok 3 is pretty good
February 18, 2025 at 8:23 PM
I’ve got to admit it, Grok 3 is pretty good
Reposted by Stephane Vandenabeele
John Textor vient de balayer ce qui était arrivé de mieux à l’OL depuis 10 ans.
Fauché dans la fleur de Sage
Le passage reste réussi pour Pierre…
www.sofoot.com
January 28, 2025 at 7:22 AM
John Textor vient de balayer ce qui était arrivé de mieux à l’OL depuis 10 ans.
Reposted by Stephane Vandenabeele
EU medicines agency quits X & moves to Bluesky
"EMA will no longer post updates and content on X. We believe the X platform no longer suits our communication needs” the agency said in a statement
www.reuters.com/world/europe...
"EMA will no longer post updates and content on X. We believe the X platform no longer suits our communication needs” the agency said in a statement
www.reuters.com/world/europe...
EU medicines agency quits X, moves to Bluesky
The European Medicines Agency (EMA) said on Monday it would no longer post on X and would use rival Bluesky instead, becoming the latest organisation to quit a social media platform that some have criticised for its content.
www.reuters.com
January 27, 2025 at 6:36 PM
EU medicines agency quits X & moves to Bluesky
"EMA will no longer post updates and content on X. We believe the X platform no longer suits our communication needs” the agency said in a statement
www.reuters.com/world/europe...
"EMA will no longer post updates and content on X. We believe the X platform no longer suits our communication needs” the agency said in a statement
www.reuters.com/world/europe...
Reposted by Stephane Vandenabeele
A terrifying new report by John Carreyrou illustrates why we have those pesky regulations and those irritating clinical trials:
Killing Cancer Patients (Once the Payments Clear)
www.science.org
January 23, 2025 at 7:52 PM
A terrifying new report by John Carreyrou illustrates why we have those pesky regulations and those irritating clinical trials:
Reposted by Stephane Vandenabeele
Infamous paper that popularized unproven COVID-19 treatment finally retracted
Study on hydroxychloroquine by Didier Raoult and colleagues gets pulled on ethical and scientific grounds
@cathleenogrady.bsky.social reports.
www.science.org/content/arti...
Study on hydroxychloroquine by Didier Raoult and colleagues gets pulled on ethical and scientific grounds
@cathleenogrady.bsky.social reports.
www.science.org/content/arti...
Infamous paper that popularized unproven COVID-19 treatment finally retracted
Study on hydroxychloroquine by Didier Raoult and colleagues gets pulled on ethical and scientific grounds
www.science.org
December 17, 2024 at 8:41 PM
Infamous paper that popularized unproven COVID-19 treatment finally retracted
Study on hydroxychloroquine by Didier Raoult and colleagues gets pulled on ethical and scientific grounds
@cathleenogrady.bsky.social reports.
www.science.org/content/arti...
Study on hydroxychloroquine by Didier Raoult and colleagues gets pulled on ethical and scientific grounds
@cathleenogrady.bsky.social reports.
www.science.org/content/arti...
Reposted by Stephane Vandenabeele
"We cannot continue to participate in the social network feed of a man who proclaims the death of the media and therefore of journalists... X is a platform that no longer serves the public interest at all, but the special ideological and financial interests of its owner and his political allies"
European Federation of Journalists to stop posting content on X
The EFJ represents over 295,000 journalists in 44 countries.
www.thelondoneconomic.com
December 2, 2024 at 3:12 PM
"We cannot continue to participate in the social network feed of a man who proclaims the death of the media and therefore of journalists... X is a platform that no longer serves the public interest at all, but the special ideological and financial interests of its owner and his political allies"
Reposted by Stephane Vandenabeele
Eli Lilly and Novo Nordisk’s Obesity Moat Just Got Stronger
“A 20% weight loss would have been best-in-class if it came a few years ago, but at this point, Novo Nordisk and Eli Lilly have drugs in the pipeline that could meet or exceed 25% weight loss,”
“A 20% weight loss would have been best-in-class if it came a few years ago, but at this point, Novo Nordisk and Eli Lilly have drugs in the pipeline that could meet or exceed 25% weight loss,”
Eli Lilly and Novo Nordisk’s Obesity Moat Just Got Stronger
Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.
buff.ly
December 1, 2024 at 9:48 AM
Eli Lilly and Novo Nordisk’s Obesity Moat Just Got Stronger
“A 20% weight loss would have been best-in-class if it came a few years ago, but at this point, Novo Nordisk and Eli Lilly have drugs in the pipeline that could meet or exceed 25% weight loss,”
“A 20% weight loss would have been best-in-class if it came a few years ago, but at this point, Novo Nordisk and Eli Lilly have drugs in the pipeline that could meet or exceed 25% weight loss,”
Reposted by Stephane Vandenabeele
November 26, 2024 at 6:27 PM
Reposted by Stephane Vandenabeele
My colleague Max Bayer unpacks one of the drug industry's most-anticipated readouts of 2024 — Amgen's potential obesity drug, MariTide.
Investors had hyped up this candidate's prospects, to the point where Amgen's stock is down 11% this morning, erasing about $14 billion in company value
Investors had hyped up this candidate's prospects, to the point where Amgen's stock is down 11% this morning, erasing about $14 billion in company value
Amgen's MariTide data are here:
- 20% weight loss at 52 wks for patients obese/overweight
- 17% weight loss at 52 weeks for patients obese/overweight + T2D
- in DE arms (~100 out of 600 ph. 2 patients) GI dropout rate was less than 8%
endpts.com/amgens-once-...
- 20% weight loss at 52 wks for patients obese/overweight
- 17% weight loss at 52 weeks for patients obese/overweight + T2D
- in DE arms (~100 out of 600 ph. 2 patients) GI dropout rate was less than 8%
endpts.com/amgens-once-...
Amgen’s once-a-month obesity shot shows 20% weight loss after a year
Amgen’s long-anticipated weight loss data are here, with MariTide spurring an average of 20% weight loss after one year for patients who are overweight or obese.
endpts.com
November 26, 2024 at 2:46 PM
My colleague Max Bayer unpacks one of the drug industry's most-anticipated readouts of 2024 — Amgen's potential obesity drug, MariTide.
Investors had hyped up this candidate's prospects, to the point where Amgen's stock is down 11% this morning, erasing about $14 billion in company value
Investors had hyped up this candidate's prospects, to the point where Amgen's stock is down 11% this morning, erasing about $14 billion in company value
Reposted by Stephane Vandenabeele
I was surprised a Biotech Investor starter pack wasn’t available, so I made one. Please help grow this community.
go.bsky.app/GV6usnz
go.bsky.app/GV6usnz
November 24, 2024 at 1:50 PM
I was surprised a Biotech Investor starter pack wasn’t available, so I made one. Please help grow this community.
go.bsky.app/GV6usnz
go.bsky.app/GV6usnz
Reposted by Stephane Vandenabeele
November 20, 2024 at 1:27 PM
Reposted by Stephane Vandenabeele
Children who develop two independent tumors during childhood are extremely rare
We wanted to see if our genomic technologies could shed light into those exceptional cases.
Read about it in this recent paper:
tinyurl.com/yt9m584d
We wanted to see if our genomic technologies could shed light into those exceptional cases.
Read about it in this recent paper:
tinyurl.com/yt9m584d
November 25, 2024 at 3:07 PM
Children who develop two independent tumors during childhood are extremely rare
We wanted to see if our genomic technologies could shed light into those exceptional cases.
Read about it in this recent paper:
tinyurl.com/yt9m584d
We wanted to see if our genomic technologies could shed light into those exceptional cases.
Read about it in this recent paper:
tinyurl.com/yt9m584d
Reposted by Stephane Vandenabeele
Roche to acquire Poseida Therapeutics for $1B upfront, $1.5B total deal value
Transposons for the win!
$PSTX
investors.poseida.com/news-release...
Transposons for the win!
$PSTX
investors.poseida.com/news-release...
investors.poseida.com
November 26, 2024 at 6:33 AM
Roche to acquire Poseida Therapeutics for $1B upfront, $1.5B total deal value
Transposons for the win!
$PSTX
investors.poseida.com/news-release...
Transposons for the win!
$PSTX
investors.poseida.com/news-release...
Reposted by Stephane Vandenabeele
Cell Therapies/bispecifics pursuing "chasing" the next dream - Autoimmune diseases
Below - upcoming milestones
Source: Cowen
Below - upcoming milestones
Source: Cowen
November 25, 2024 at 2:31 AM
Cell Therapies/bispecifics pursuing "chasing" the next dream - Autoimmune diseases
Below - upcoming milestones
Source: Cowen
Below - upcoming milestones
Source: Cowen
Reposted by Stephane Vandenabeele
X now marks the spot for misinformation, anti-science, lack of moderation
Why this cancer patient and advocate is walking away from X. (Hint: it’s not politics)
I've been living with and communicating about lung cancer for over 13 years. Since 2011…
http://grayconnections.net/2024/11/16/why-this-cancer-patient-and-advocate-is-walking-away-from-x-hint-its-not-politics/
I've been living with and communicating about lung cancer for over 13 years. Since 2011…
http://grayconnections.net/2024/11/16/why-this-cancer-patient-and-advocate-is-walking-away-from-x-hint-its-not-politics/
November 22, 2024 at 12:36 PM
X now marks the spot for misinformation, anti-science, lack of moderation